[
  {
    "ts": null,
    "headline": "Gilead, LEO Pharma partner to develop programs for inflammatory diseases",
    "summary": "Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will be...",
    "url": "https://finnhub.io/api/news?id=adf5eaf3aa1a062c8f60e8701ba8d540e80152c6ffabccc0b695d21e67b91875",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736599196,
      "headline": "Gilead, LEO Pharma partner to develop programs for inflammatory diseases",
      "id": 132378258,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will be...",
      "url": "https://finnhub.io/api/news?id=adf5eaf3aa1a062c8f60e8701ba8d540e80152c6ffabccc0b695d21e67b91875"
    }
  },
  {
    "ts": null,
    "headline": "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases",
    "summary": "-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders ---- Gilead...",
    "url": "https://finnhub.io/api/news?id=2076817123bd513dba0af03e2aafaef25b55ca7a1a455b8ca43b90e0152a444b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736593263,
      "headline": "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases",
      "id": 132377924,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders ---- Gilead...",
      "url": "https://finnhub.io/api/news?id=2076817123bd513dba0af03e2aafaef25b55ca7a1a455b8ca43b90e0152a444b"
    }
  }
]